Aptose Biosciences (TSE:APS)
TSX:APS
Want to see TSE:APS full AI Analyst Report?
Top Page
Aptose Biosciences
(TSX:APS)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$2.50
▲(15.74% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial fundamentals (no revenue, sizable ongoing losses, significant cash burn, and balance-sheet strain with negative equity and rising debt). Technicals provide some offset as price is above key moving averages with neutral RSI, but valuation offers limited support given negative earnings and no dividend yield data.
Positive Factors
Focused clinical-stage pipeline
Aptose’s concentrated pipeline with two lead clinical kinase inhibitors provides clear R&D focus and prioritization. Sustained focus on advancing tuspetinib and luxeptinib supports durable value creation if trials progress, concentrating resources on high-impact development milestones.
Negative Factors
No commercial revenue
Absent any product revenue, Aptose must rely entirely on financing to fund development. Persistent operating losses (TTM net loss ~-$27.6M) mean limited internal cash generation, making long-term sustainability contingent on successful trials or external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused clinical-stage pipeline
Aptose’s concentrated pipeline with two lead clinical kinase inhibitors provides clear R&D focus and prioritization. Sustained focus on advancing tuspetinib and luxeptinib supports durable value creation if trials progress, concentrating resources on high-impact development milestones.
Read all positive factors
Aptose Biosciences (APS) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.95M
Dividend YieldN/A
Average Volume (3M)3.35K
Price to Earnings (P/E)―
Beta (1Y)-0.98
Revenue GrowthN/A
EPS Growth60.66%
CountryCA
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.80
Shares Outstanding2,552,429
10 Day Avg. Volume4,664
30 Day Avg. Volume3,346
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.14
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.65
Revenue Forecast (FY)N/A
Aptose Biosciences Business Overview & Revenue Model
Company Description
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/...
How the Company Makes Money
null...
Aptose Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -425.32K | 0.00 | -474.55K | -507.08K | -616.53K |
| EBITDA | -24.73M | -26.23M | -52.27M | -42.48M | -65.30M |
| Net Income | -25.91M | -25.43M | -51.21M | -41.82M | -65.35M |
Balance Sheet | |||||
| Total Assets | 9.99M | 10.13M | 12.99M | 51.03M | 82.53M |
| Cash, Cash Equivalents and Short-Term Investments | 4.09M | 6.15M | 9.25M | 46.96M | 79.13M |
| Total Debt | 28.01M | 10.64M | 1.01M | 1.30M | 574.00K |
| Total Liabilities | 37.11M | 14.67M | 15.89M | 13.29M | 8.29M |
| Stockholders Equity | -27.12M | -4.54M | -2.90M | 37.74M | 74.24M |
Cash Flow | |||||
| Free Cash Flow | -22.37M | -35.98M | -44.62M | -32.35M | -43.52M |
| Operating Cash Flow | -22.37M | -35.98M | -44.59M | -32.32M | -43.30M |
| Investing Cash Flow | 0.00 | 18.00K | 9.96M | 30.07M | -35.21M |
| Financing Cash Flow | 19.72M | 33.41M | 6.91M | 116.00K | 226.00K |
Aptose Biosciences Technical Analysis
Positive
2.16
Price Trends
2.29
Positive
2.24
Positive
2.05
Positive
Market Momentum
<0.01
Negative
53.22
Neutral
81.42
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APS, the sentiment is Positive. The current price of 2.16 is below the 20-day moving average (MA) of 2.29, below the 50-day MA of 2.29, and above the 200-day MA of 2.05, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.22 is Neutral, neither overbought nor oversold. The STOCH value of 81.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:APS.
Aptose Biosciences Risk Analysis
Aptose Biosciences disclosed 57 risk factors in its most recent earnings report. Aptose Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aptose Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$9.11M | -6.03 | 19.14% | ― | ― | 62.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$5.95M | -0.14 | 123.88% | ― | ― | 60.66% | |
45 Neutral | C$4.33M | -6.13 | -111.11% | ― | ― | -79.26% | |
44 Neutral | C$6.00M | -2.97 | ― | ― | ― | ― | |
| ― | C$2.04M | -1.60 | ― | ― | ― | 25.09% |
* Healthcare Sector Average
TSE:APS
Aptose Biosciences
2.38
0.02
0.85%
TSE:XRTX
XORTX Therapeutics Inc
3.05
-3.50
-53.43%
TSE:KNE
Kane Biotech
0.03
-0.03
-45.00%
TSE:QPT
Quest Pharmatech
0.03
>-0.01
-14.29%
TSE:BETR
BetterLife Pharma
0.06
-0.04
-40.00%
TSE:BIOV
BioVaxys Technology
0.07
-0.28
-80.00%
Aptose Biosciences Corporate Events
Business Operations and StrategyM&A TransactionsShareholder Meetings
ISS Backs Hanmi’s Cash Takeover of Aptose Ahead of March 31 Vote
Positive
Mar 19, 2026
Aptose Biosciences said proxy adviser Institutional Shareholder Services has recommended that investors back its proposed plan of arrangement under which Hanmi Pharmaceutical and its subsidiary would acquire all Aptose shares they do not already o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.